Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.43 |
| ▸ | RET | P07949 | 10/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.41 |
| ▸ | TTK | P33981 | 2/20 | 0.40 |
| ▸ | WNT1 | P04628 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
| ▸ | YES1 | P07947 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15257727 | 0.87 | RET (0.46) | GSK3BDYRK1ARETGPR119USP30 | |
| SCHEMBL12291796 | 0.86 | MKNK1 (0.37) | RETMAPK1AURKBABL1 | |
| SCHEMBL9887901 | 0.85 | PDPK1 (0.41) | — | |
| SCHEMBL13385882 | 0.84 | ALK (0.41) | MAPK1AURKB | |
| SCHEMBL3804479 | 0.84 | GSK3B (0.41) | GSK3BDYRK1ARETGPR119USP30 | |
| SCHEMBL12291835 | 0.84 | CYP11B2 (0.38) | GSK3BDYRK1ARETGPR119WNT1 | |
| SCHEMBL14976706 | 0.82 | RET (0.42) | GSK3BDYRK1ARETGPR119USP30 | |
| SCHEMBL18437202 | 0.82 | GSK3B (0.41) | GSK3BDYRK1ARETGPR119USP30 | |
| SCHEMBL28507697 | 0.80 | CHEK1 (0.48) | — | |
| SCHEMBL13554546 | 0.79 | RET (0.42) | GSK3BDYRK1ARETGPR119USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3133074-B1 | 7-AZAINDOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2020-12-09 | — | — | EP | disclosed |
| US-9725446-B2 | 7-azaindole derivatives | MERCK PATENT GMBH (DE) | 2017-08-08 | — | — | US | disclosed |
| US-9725446-B2 | 7-azaindole derivatives | MERCK PATENT GMBH (DE) | 2017-08-08 | — | — | US | disclosed |
| US-9725446-B2 | 7-azaindole derivatives | MERCK PATENT GMBH (DE) | 2017-08-08 | — | — | US | disclosed |
| EP-2746281-B1 | 7-azaindole derivatives | MERCK PATENT GMBH (DE) | 2017-04-26 | — | — | EP | disclosed |
| EP-3133074-A2 | 7-AZAINDOLE DERIVATIVES | Merck Patent GmbH (DE) | 2017-02-22 | — | — | EP | disclosed |
| EP-2670748-B1 | 7-AZAINDOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-09-28 | — | — | EP | disclosed |
| US-20160130269-A1 | 7-AZAINDOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-05-12 | — | — | US | disclosed |
| US-20160130269-A1 | 7-AZAINDOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-05-12 | — | — | US | disclosed |
| US-20160130269-A1 | 7-AZAINDOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-05-12 | — | — | US | disclosed |
| US-20120053178-A1 | 3-(1,2,3-Triazol-4-yl) pyrrolo [2,3-b] pyridine derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-03-01 | — | — | US | disclosed |
| US-20120053178-A1 | 3-(1,2,3-Triazol-4-yl) pyrrolo [2,3-b] pyridine derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-03-01 | — | — | US | disclosed |
| US-20120053178-A1 | 3-(1,2,3-Triazol-4-yl) pyrrolo [2,3-b] pyridine derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-03-01 | — | — | US | disclosed |
| US-20110082140-A1 | 6-(PYRROLOPYRIDINYL) PYRIMIDIN-2-YLAMINE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF CANCER AND AIDS. | MERCK PATENT GMBH (DE) | 2011-04-07 | — | — | US | disclosed |
| US-20110082140-A1 | 6-(PYRROLOPYRIDINYL) PYRIMIDIN-2-YLAMINE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF CANCER AND AIDS. | MERCK PATENT GMBH (DE) | 2011-04-07 | — | — | US | disclosed |
| US-20110082140-A1 | 6-(PYRROLOPYRIDINYL) PYRIMIDIN-2-YLAMINE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF CANCER AND AIDS. | MERCK PATENT GMBH (DE) | 2011-04-07 | — | — | US | disclosed |
| WO-2010127754-A1 | 3-([1,2,3]TRIAZOLE-4-YL)-PYRROLO[2,3-B]PYRIDINE DERIVATES | MERCK PATENT GMBH (DE) | 2010-11-11 | — | — | WO | disclosed |
| EP-2155745-A1 | 6-(PYRROLOPYRIDINYL)-PYRIMIDINE-2-YL-AMINE DERIVATIVES | Merck Patent GmbH (DE) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008155000-A1 | 6-(PYRROLOPYRIDINYL)-PYRIMIDINE-2-YL-AMINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008155000-A1 | 6-(PYRROLOPYRIDINYL)-PYRIMIDINE-2-YL-AMINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082140-A1 | 6-(PYRROLOPYRIDINYL) PYRIMIDIN-2-YLAMINE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF CANCER AND AIDS. | MKI67, TYMP, TK2 | GSK3B 2512/4885DYRK1A 1598/4885RET 1357/4885 |
| US-20120053178-A1 | 3-(1,2,3-Triazol-4-yl) pyrrolo [2,3-b] pyridine derivatives | PDK1, PDK2, PDK3 | GSK3B 347/4885DYRK1A 633/4885RET 537/4885 |
| US-20160130269-A1 | 7-AZAINDOLE DERIVATIVES | PDK1, PDK2, PDK3 | GSK3B 412/4885DYRK1A 998/4885RET 776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.